This was demonstrated by Abu-Yousif et al., who conjugated a benzoporphyrin derivative to an EGFR-targeting antibody (cetuximab) to combat EGFR-positive ovarian cancer cells [29]. The gene discussed is EGFR; the disease is ovarian cancer.